Cord Blood News 8.38 September 29, 2016 | |
| |
TOP STORYUsing a previously described in vitro system for efficient derivation of hematopoietic cells from human pluripotent stem cells, scientists showed that the vast majority of generated hematopoietic cells display supraphysiological levels of reactive oxygen species compared to fresh cord blood cells. [Stem Cells] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The authors showed that proliferation, differentiation, phenotype stability, and cytokine secretion by umbilical cord mesenchymal stem cells (UC-MSCs) vary depending on the type of xeno-free media. [J Mol Med] Abstract The authors evaluated the differentiation potential and immunogenicity of human placenta-derived mesenchymal stem cells manipulated with osteogenic priming and dedifferentiation process. [Stem Cell Res Ther] Full Article Researchers investigated whether exosomes released from Akt-overexpressing mesenchymal stem cells showed a beneficial effect on cardioprotection and angiogenesis. [Stem Cells Transl Med] Abstract Umbilical cord human mesenchymal stem cells (UC MSCs) from twenty four pregnant women along with placentas were collected upon delivery. The UC MSCs of obese mothers displayed less potential toward osteoblastogenesis and more towards adipogenesis. [Endocrinology] Abstract To evaluate the clinical impact of donor source on allogeneic hematopoietic stem cell transplantation (allo-HSCT) in childhood acute leukemia, scientists analyzed data from 577 children who underwent allo-HSCT following the myeloablative regimen during the first or second complete remission in 2005–2012, using registry data of the Japan Society for Hematopoietic Cell Transplantation, and compared outcomes of 7–8/8 human leukocyte antigen (HLA) allelic-matched unrelated bone marrow transplantation and 4–6/6 HLA allelic-matched unrelated cord blood transplantation to those of HLA identical related bone marrow transplantation. [Biol Blood Marrow Transplant] Abstract Investigators evaluated the safety and efficacy of thiotepa-based regimens before allogeneic stem cell transplantation in 310 adult patients with AML. Transplantation was performed from haploidentical, matched sibling, unrelated or cord blood donors. [Bone Marrow Transplant] Abstract Intrathecally transplanted human umbilical cord-derived mesenchymal stem cells were utilized to examine the effect on neuropathic pain induced by a rat model with spinal nerve ligation, so as to explore the possible mechanism of those effects. [Neurochem Res] Abstract Scientists identified the signatures miRNAs implicated in hepatic differentiation of stem cells using next generation sequencing method. They performed sequencing of microRNAs isolated from three different time points during hepatic differentiation of human umbilical cord Wharton’s jelly derived mesenchymal stem cells from two biological replicates. [Hepatol Res] Abstract | |
| |
REVIEWSHematopoietic Stem Cell Transplantation in Inborn Errors of Metabolism The authors summarize the main results of hematopoietic stem cell transplantation in selected inborn errors of metabolism. [Curr Opin Hematol] Abstract Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSJanssen Research & Development, LLC announced that a supplemental New Drug Application for ibrutinib (IMBRUVICA®) has been submitted to the U.S. Food and Drug Administration for the treatment of patients with marginal zone lymphoma who require systemic therapy. The filing is based on data from the multi-center, open-label Phase II PCYC-1121 trial assessing the use of ibrutinib, a BTK inhibitor, in patients with MZL who have received at least one prior therapy. [Janssen Research & Development, LLC] Press Release Kite Pharma, Inc. announced positive topline results from a pre-planned interim analysis of ZUMA-1 for its lead product candidate, KTE-C19, in patients with chemorefractory diffuse large B-cell lymphoma. KTE-C19 met the primary endpoint of objective response rate (ORR) with 76 percent, including 47 percent complete remissions. [Kite Pharma, Inc.] Press Release Syros Pharmaceuticals announced that the first patient has been dosed in the Phase II clinical trial of its lead drug candidate, SY-1425, a first-in-class selective retinoic acid receptor alpha agonist, in genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome identified using a novel biomarker discovered by its gene control platform. [Syros Pharmaceuticals] Press Release | |
| |
POLICY NEWSScience Spending Boosted in French Budget France’s government has proposed an unusually generous boost to research and higher education in its 2017 draft budget. This is the largest increase for 15 years,” Thierry Mandon, France’s research and higher-education minister, told reporters at a press conference. [Nature News] Editorial Open-Access Journal eLife to Start Charging Fees The open-access journal eLife is dropping one of its most distinctive features: free publishing. From 2017, it will charge a fee of $2,500 for all accepted papers. [Nature News] Editorial Tensions between Cuba and the United States are easing. But researchers still struggle to join the scientific world. [Nature News] Editorial Validate Your Antibodies to Improve Reproducibility? Easier Said than Done More than 100 researchers, antibody manufacturers, journal editors, and funders met in Pacific Grove, California, to hash out standardized approaches to antibody testing. [Science Insider] Editorial Documents Reveal Intense Battle over CDC Zika Tests A protracted battle between a Zika expert at the U.S. Centers for Disease Control and Prevention and his superiors over tests for the virus came to light yesterday. He alleges that the agency’s Emergency Operations Center discounted his research in April and created “a public health threat” by relying on a less dependable human test for the Zika virus. [Science Insider] Editorial
| |
EVENTSNEW Advances in Cell Engineering, Imaging and Screening NEW The 2nd Int’l Conference on Clinical and Experimental Hematology (ICCEH 2016) Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Blood Coagulation and Progenitor Cells (BloodCenter of Wisconsin) NEW Research Associate – Hematology (Editas Medicine) Postdoctoral Associate Position – Blood Cancer and Epigenetic Research (University of Miami) Chair – Medical Biology (Masaryk University) PhD Position – Tumor Microenvironment in Leukemia (Georg-Speyer-Haus) Research Fellow – Cancer Biology (University of Michigan) Assistant Member Faculty – PlatinumImmunotherapy (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|